Company Analysis

Summit Therapeutics Inc. (SMMT)

Nasdaq: SMMT · Pharmaceutical Preparations · Miami, FL · filing with the SEC since 2014
Grade5.2
◀ Past 3.7● Present 4.9▶ Future 6.5
4 est.

Who runs Summit Therapeutics Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Duggan Robert W
Co-Chief Executive Officer. First filing Sep 2020, latest Jun 12, 2026, 8 filings in all.
Officers reporting now
4
of 10 people with a filing in the last fifteen months
Directors reporting now
6
21 people on the record since 2020
Officerssales are open-market, Oct 14, 2025 to Oct 14, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Anand BhaskarChief Accounting OfficerApr 2024Oct 14, 2026none
Duggan Robert WCo-Chief Executive OfficerSep 2020Jun 12, 2026none
Zanganeh MakyCo-Chief Executive OfficerNov 2020Jun 12, 2026none
Soni Manmeet SinghCOO and CFOSep 2020Jun 4, 2026none
Directorssales are open-market, Oct 14, 2025 to Oct 14, 2026
NameRoleFirst filingLatest filingSales, 12 months
Booth Robert F.directorOct 2022Jan 6, 2026none
Cesano AlessandradirectorNov 2022Jan 6, 2026none
Clark Kenneth AdirectorOct 2021Jan 6, 2026none
Huber JeffdirectorJun 2024Jan 6, 2026none
Ronaghi MostafadirectorApr 2024Jan 6, 2026none
Xia YudirectorJan 2023Jan 6, 2026none
Earlier names on the record11, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton SMMT · research, not advice